Gastric Cancer, Gastroesophageal-junction Cancer
Conditions
Keywords
T Cell Receptor, Gastric Cancer, Gastroesophageal-junction Cancer
Brief summary
To observe and determine the safety, tolerability, cellular pharmacokinetics and efficacy of TCRx T cells in patients with advanced or recurrent gastric/gastroesophageal junction cancer after failure of first chemotherapy.
Detailed description
1. Sign the informed consent for clinical trials 2. Subject screening 3. Extract the blood of the subjects and isolate the PBMC 4. Find a patient-specific tumor-specific TCR sequence combination, which is a multi-targeted tumor-specific combination. 5. Transfer of personalized tumor-specific TCRs into patient autologous CD8 T cells by gene editing 6. Large-scale culture and expansion of gene-edited T cells 7. T cell viability, infection efficiency and microbial detection in hospital 8. Calculate the number of cells in the patient's body according to TCRx T 9. Injecting TCRx T cells back into the subject 10. Within 7 days after the injection, the subject's post-dose reaction should be closely observed in the hospital 11. After the first injection, continue to reinfuse TCRx T cells up to 4 times according to the treatment effect and the incidence of adverse events, and be hospitalized after each injection to closely monitor possible adverse events
Interventions
BIOLOGICALTcrx T cell
Sequential IV infusion
Sponsors
TCRx Therapeutics Co.Ltd
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
① 1x10\^7/m2 * 3x10\^7/m2； * 1x10\^8/m2； * 3x10\^8/m2； * 1x10\^9/m2。
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-70 years old; 2. Histologically confirmed advanced/locally advanced or metastatic gastric cancer at the stomach or gastroesophageal junction, progressed after first-line chemotherapy, or recurrence after gastric/gastroesophageal junction surgery combined with neoadjuvant/adjuvant chemotherapy 3. Expected survival time ≥ 3 months 4. Eastern Cooperative Oncology Group (ECOG) score 0-2 5. According to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1), at least one one-dimensional, measurable tumor (short-axis diameter greater than 1 cm) 6. Normal bone marrow hematopoietic function: (leukocytes≥4000 cells/㎕, neutrophils≥1500 cells/㎕, platelet counts≥100000 cells/㎕) 7. Normal liver and kidney function: serum bilirubin \<1.5mg/dl, AST (SGOT) and ALT (SGPT) \<2.5UNL, alkaline phosphatase \<5UNL; serum creatinine \<1.5mg/dl; 8. Men and women must take appropriate contraceptive measures.
Exclusion criteria
1. Patients with previous non-gastric/gastroesophageal junction malignant tumor 2. History of severe acute allergy 3. There is an uncontrolled infection 4. History or clinical evidence of central nervous system (CNS) metastasis or leptomeningeal carcinomatosis 5. History of cerebrovascular accident within the past 6 months, including transient ischemic attack (TIA), pulmonary embolism or untreated deep vein thrombosis (DVT) 6. History of one or more of the following cardiovascular diseases within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass grafting, symptomatic peripheral vascular disease , NYHA type III or IV congestive heart failure 7. Poor control of hypertension 8. QT interval \>480ms 9. Evidence of active bleeding or bleeding tendency 10. Clinically significant gastrointestinal abnormalities, such as bleeding, obstruction, and high risk of perforation 11. Grade 3 or 4 diarrhea 12. Any serious and/or unstable previous medical, psychiatric, or other circumstances that may affect subject safety, provide informed consent, or comply with research procedures 13. Unable or unwilling to stop using illicit drugs for at least 14 days or drug half-life (whichever is longer) before and during the first study drug administration 14. Treated with any of the following anticancer therapies: radiotherapy, tumor embolization or chemotherapy, immunotherapy, biological therapy within 14 days before the first dose; neoadjuvant chemotherapy or adjuvant chemotherapy must be at least 6 months before the start of the study Finish 15. Any persistent toxicity greater than grade 1 and/or worsening in severity from prior anticancer therapy, except for alopecia 16. Participate in a clinical trial of another investigational drug within 30 days prior to the start of the study 17. Pregnant or lactating women 18. Men or women planning to become pregnant within the next six months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tumor volume | about 2 years | RECIST 1.1 |
| Overall Survival | about 2 years | The time from randomization to death due to any reason. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AEs | about 2 years | CTCAE5.0 |
Outcome results
None listed